410 filings
Page 5 of 21
8-K
4o72y10nz41hx 3w
18 Nov 22
Other Events
8:17am
8-K
a6s9b7 bl83j
9 Nov 22
KemPharm Reports Third Quarter 2022 Results
4:24pm
8-K
03ak60q
11 Aug 22
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
4:25pm
8-K
cavu6q1b
1 Jul 22
Submission of Matters to a Vote of Security Holders
8:32am
DEFA14A
m20bik
17 Jun 22
Additional proxy soliciting materials
9:17am
8-K
3typkd5xr8 wjo15w3mo
17 Jun 22
Changes in Registrant's Certifying Accountant
9:14am
8-K
3qjbhgdip84nym ll
31 May 22
Entry into a Material Definitive Agreement
9:13pm
8-K
q31rbkc7e
16 May 22
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
8:40am
DEFA14A
d6tbbs25 jlq2aqvx
12 May 22
Additional proxy soliciting materials
5:26pm
8-K
vqk0m
12 May 22
KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates
4:48pm
8-K
2g3x2
30 Mar 22
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
4:36pm
8-K
hn59fp4 az9rsow8i
21 Mar 22
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
8:49am
8-K
ak9buxzrxj50afqodg9s
16 Mar 22
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement
8:32am
8-K
8b44tj
22 Feb 22
Regulation FD Disclosure
9:09am
424B3
rrmxf4juemnqr3j
2 Feb 22
Prospectus supplement
4:16pm